Elevated Pro-inflammatory and Lipotoxic Mucosal Lipids Characterise Irritable Bowel Syndrome

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2009 Dec 23

PMID 20027679

Citations 17

Authors

Kajsa Kajander

Eveliina Myllyluoma

Sinikka Kyronpalo

Martin Rasmussen

Pentti Sipponen

Ismo Mattila

Tuulikki Seppanen-Laakso

Heikki Vapaatalo

Matej Oresic

Riitta Korpela

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the pathophysiology of irritable bowel syndrome (IBS) by comparing the global mucosal metabolic profiles of IBS patients with those of healthy controls.

Methods: Fifteen IBS patients fulfilling the Rome II criteria, and nine healthy volunteers were included in the study. A combined lipidomics (UPLC/MS) and metabolomics (GC x GC-TOF) approach was used to achieve global metabolic profiles of mucosal biopsies from the ascending colon.

Results: Overall, lipid levels were elevated in patients with IBS. The most significant upregulation was seen for pro-inflammatory lysophosphatidylcholines. Other lipid groups that were significantly upregulated in IBS patients were lipotoxic ceramides, glycosphingolipids, and di- and triacylglycerols. Among the metabolites, the cyclic ester 2(3H)-furanone was almost 14-fold upregulated in IBS patients compared to healthy subjects (P = 0.03).

Conclusion: IBS mucosa is characterised by a distinct pro-inflammatory and lipotoxic metabolic profile. Especially, there was an increase in several lipid species such as lysophospholipids and ceramides.

Citing Articles

Characterisation of the Plasma and Faecal Metabolomes in Participants with Functional Gastrointestinal Disorders.

Fraser K, James S, Young W, Gearry R, Heenan P, Keenan J Int J Mol Sci. 2025; 25(24.

PMID: 39769229 PMC: 11677738. DOI: 10.3390/ijms252413465.

Multi-Omics Analysis of Gut Microbiota and Host Transcriptomics Reveal Dysregulated Immune Response and Metabolism in Young Adults with Irritable Bowel Syndrome.

Chen J, Zhao T, Li H, Xu W, Maas K, Singh V Int J Mol Sci. 2024; 25(6).

PMID: 38542485 PMC: 10970623. DOI: 10.3390/ijms25063514.

Metabolomic Profile of Different Dietary Patterns and Their Association with Frailty Index in Community-Dwelling Older Men and Women.

Tanaka T, Talegawkar S, Jin Y, Candia J, Tian Q, Moaddel R Nutrients. 2022; 14(11).

PMID: 35684039 PMC: 9182888. DOI: 10.3390/nu14112237.

Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.

Gardner A, Haq I, Simpson A, Becker K, Gallagher J, Saint-Criq V Am J Respir Crit Care Med. 2020; 202(8):1133-1145.

PMID: 32569477 PMC: 7560813. DOI: 10.1164/rccm.202001-0180OC.

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.

Zhuang X, Tian Z, Luo M, Xiong L BMC Gastroenterol. 2020; 20(1):187.

PMID: 32532214 PMC: 7291629. DOI: 10.1186/s12876-020-01336-6.

References

Schnackenberg L, Beger R . Monitoring the health to disease continuum with global metabolic profiling and systems biology. Pharmacogenomics. 2006; 7(7):1077-86. DOI: 10.2217/14622416.7.7.1077. View

Tornblom H, Lindberg G, Nyberg B, Veress B . Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002; 123(6):1972-9. DOI: 10.1053/gast.2002.37059. View

Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell G, Santini D . Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004; 126(3):693-702. DOI: 10.1053/j.gastro.2003.11.055. View

Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J . The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007; 133(1):24-33. DOI: 10.1053/j.gastro.2007.04.005. View

Clark J . The creatine kinase system in smooth muscle. Mol Cell Biochem. 1994; 133-134:221-32. DOI: 10.1007/BF01267956. View

Sawai T, Lampman R, Hua Y, Segura B, Drongowski R, Coran A . Lysophosphatidylcholine alters enterocyte monolayer permeability via a protein kinase C/Ca2+ mechanism. Pediatr Surg Int. 2002; 18(7):591-4. DOI: 10.1007/s00383-002-0860-x. View

Katajamaa M, Oresic M . Processing methods for differential analysis of LC/MS profile data. BMC Bioinformatics. 2005; 6:179. PMC: 1187873. DOI: 10.1186/1471-2105-6-179. View

Drossman D, Camilleri M, Mayer E, Whitehead W . AGA technical review on irritable bowel syndrome. Gastroenterology. 2002; 123(6):2108-31. DOI: 10.1053/gast.2002.37095. View

Summers S . Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006; 45(1):42-72. DOI: 10.1016/j.plipres.2005.11.002. View

10.

Bearcroft C, Perrett D, Farthing M . Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut. 1998; 42(1):42-6. PMC: 1726971. DOI: 10.1136/gut.42.1.42. View

11.

Haapamaki M, Gronroos J, Nurmi H, Irjala K, Alanen K, Nevalainen T . Phospholipase A2 in serum and colonic mucosa in ulcerative colitis. Scand J Clin Lab Invest. 1999; 59(4):279-87. DOI: 10.1080/00365519950185643. View

12.

Assimakopoulos S, Vagianos C, Patsoukis N, Georgiou C, Nikolopoulou V, Scopa C . Evidence for intestinal oxidative stress in obstructive jaundice-induced gut barrier dysfunction in rats. Acta Physiol Scand. 2004; 180(2):177-85. DOI: 10.1046/j.0001-6772.2003.01229.x. View

13.

Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J . Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006; 66(22):10795-804. DOI: 10.1158/0008-5472.CAN-06-0755. View

14.

Thompson W, Longstreth G, Drossman D, Heaton K, Irvine E, Muller-Lissner S . Functional bowel disorders and functional abdominal pain. Gut. 1999; 45 Suppl 2:II43-7. PMC: 1766683. DOI: 10.1136/gut.45.2008.ii43. View

15.

Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A . Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002; 122(7):1778-83. DOI: 10.1053/gast.2002.33579. View

16.

Dinan T, Quigley E, Ahmed S, Scully P, OBrien S, OMahony L . Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. Gastroenterology. 2006; 130(2):304-11. DOI: 10.1053/j.gastro.2005.11.033. View

17.

Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S . Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007; 132(3):913-20. DOI: 10.1053/j.gastro.2007.01.046. View

18.

Philip Malan Jr T, Porreca F . Lipid mediators regulating pain sensitivity. Prostaglandins Other Lipid Mediat. 2005; 77(1-4):123-30. DOI: 10.1016/j.prostaglandins.2004.09.008. View

19.

Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M . Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut. 1994; 35(11):1593-8. PMC: 1375618. DOI: 10.1136/gut.35.11.1593. View

20.

Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T . Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med. 2001; 31(6):717-28. DOI: 10.1016/s0891-5849(01)00655-4. View